Stroke Patient Articles & Analysis

Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...

By Neurolutions

ISPRM 2022 is now over | International Society of Physical and Rehabilitation Medicine | Lisbon PT After 4 nice days and some smart presentations, ISPRM 2022 now ends with great memories. New device presentation: IVS4 for Lower Limbs as a complementary approach to balance exercise, strengthening and robotic rehabilitation for gait recovery Lecture: Comparison of EEG biomarkers in Mirror ...

By Dessintey | Parc Technologique Metrotech

In the neurovascular space where speed, reliability, and performance are so critical to patient outcomes, physicians and patients demand that innovative technologies are best-in-class. The walrus BGC, with its 087 ID, marks a big step forward in balloon guide catheter technology and for stroke patients worldwide. “I expect its introduction will be welcomed by neurovascular physicians ...

By Q`Apel Medical Inc.

IpsiHand robotic hand-piece uniquely leverages brain-computer interface technology for chronic stroke rehabilitation IpsiHand also has been granted U.S. FDA Breakthrough Device Designation Neurolutions, Inc., a medical device company developing and commercializing a first-of-its-kind device leveraging brain-computer interface (BCI) technology for upper extremity chronic stroke rehabilitation, ...

By Neurolutions

Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today its successful first robotic carotid stenting at Rennes University Hospital. This breakthrough in the neurovascular field was performed on November 16, using Robocath’s R-One robot, operated by Dr. François Eugène and his team. The ...

By Robocath

Imperative Care, Inc., a company singularly dedicated to addressing unsolved problems in stroke, today announced that its Chief Operating Officer, Daniel Davis, has been appointed as the company’s President. Mr. Davis will oversee the growth of the company’s technology portfolio for the treatment of ischemic and hemorrhagic stroke. He will retain his role as COO and join the ...

By Imperative Care

JERUSALEM, Feb. 11, 2021-- BrainQ, the Israeli start-up with a therapeutic solution to reduce disability following stroke, announced today that the United States Food and Drug Administration (FDA) has designated its AI-powered technology as a Breakthrough Device. The designation, which was based on BrainQ's latest randomized controlled clinical trial results for ischemic stroke patients, ...

By BrainQ Technologies

People recovering from a stroke will soon have access to a device that can help restore a disabled hand. The Food And Drug Administration has authorized a device called IpsiHand from the uninjured side of a patient's brain to help rewire circuits controlling the hand, wrist and arm. The device can be used at home and offers stroke patients "an additional treatment option to help them ...

By Neurolutions

TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced the hiring of a new Regional Sales Director, Tony Bellofatto. Bellofatto is an award-winning Medical ...

By Bionik

We are delighted to announce that Lumosa's LT3001 (odatroltide) has been shortlisted for the "Clinical Advance of the Year Award" at this year's Pharma Intelligence Scrip Awards. This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. Other finalists include Boehringer Ingelheim and Eli Lilly's ...

By Lumosa Therapeutics Co., Ltd.

Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke. “Enrolling the first patient in this landmark study is an important milestone for ...

By Rapid Medical

BioXtreme is proud to announce that, following our ISO-13485 certification from the Israeli Standards Institution (www.sii.org.il), it has received its CE Marking, based on self declaration. The CE Marking is intended for deXtreme, our upper limb neurorehabiliatation robotic device, meant to treat stroke and other TBI patients with our novel Error Enhancement technology. By this CE Marking we ...

By BioXtreme Ltd.

Corindus, a Siemens Healthineers Company and leading developer of precision vascular robotics, announced today its CorPath® GRX System was used to complete the first-in-human robotic-assisted neurovascular intervention. The procedure was performed by the team led by Dr. Vitor Mendes Pereira, a neurosurgeon and neuroradiologist at the Toronto Western Hospital and Krembil Brain Institute in ...

By Siemens Healthcare GmbH

Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion. The Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System) is a Brain-Computer-Interface (BCI) device that assists in rehabilitation ...

By Neurolutions

Neuros Medical, Inc., a neuromodulation company, announced today the appointment of Tom Wilder as President and CEO. Mr. Wilder has over 30 years of experience, having most recently led Sequent Medical, Inc., a neurovascular company that developed the WEB Aneurysm Embolization System, where he served for six years. Sequent was acquired by Terumo Corporation in 2016 for up to $380 million. Prior ...

By Neuros Medical, Inc.

Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. The round included River Cities Capital, Soleus Capital and incumbent investor, Research Corporation Technologies (RCT). Scott Huennekens, former Chairman, CEO and ...

By Q`Apel Medical Inc.

MicroTransponder Inc., today announced that the pivotal clinical trial results for the Company's investigational Vivistim® Paired Vagus Nerve Stimulation (VNS) System have been published in The Lancet. Each year in the US, 50-60% of the 658,000 stroke survivors have upper extremity motor deficits that persist for many months to years after their stroke. The Lancet reports that patients ...

By MicroTransponder Inc. (MTI)

New 35,000 square foot Facility will support the company’s growth and OUS expansion Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today that it will relocate its existing headquarters into a new building at 4245 Technology Dr, Fremont, CA, 94538. The 35,000 ...

By Q`Apel Medical Inc.

Robocath, a company that designs, develops and commercializes robotic solutions to treat cardiovascular diseases, and Rennes University Hospital, today announce the launch of a co-development research program using robotics to improve treatment for stroke victims. With the support of Philips France, this unique program will be implemented over the next four years. It will focus on the use of ...

By Robocath

WASHINGTON, Dec. 9, 2021 – BrainQ today announced that the first patient has been enrolled at MedStar National Rehabilitation Hospital in its pivotal, randomized, double-blind, multicenter trial, EMAGINE (the BQ5 Study). The trial is evaluating its frequency-tuned electromagnetic field treatment in facilitating recovery in individuals with moderately-severe ischemic stroke. The EMAGINE ...

By BrainQ Technologies